The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
-
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States, 90720
Sharp Memorial Hospital, San Diego, California, United States, 92123
Private Practice - Dr. James R. Berenson, West Hollywood, California, United States, 90069
Local Institution - 0381, Aurora, Colorado, United States, 80045
Local Institution - 0380, Farmington, Connecticut, United States, 06030
Advanced Research, Coral Springs, Florida, United States, 33321
Local Institution - 0403, Fort Myers, Florida, United States, 33901
Local Institution - 0401, Saint Petersburg, Florida, United States, 33705
Local Institution - 0402, West Palm Beach, Florida, United States, 33401
University Cancer Blood Ctr, Athens, Georgia, United States, 30607
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Celgene,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2033-11-30